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Background: We previously established a three-dimensional (3-D) colonic crypt model using HKe3 cells which are
human colorectal cancer (CRC) HCT116 cells with a disruption in oncogenic KRAS, and revealed the crucial roles of
oncogenic KRAS both in inhibition of apoptosis and in disruption of cell polarity; however, the molecular
mechanism of KRAS-induced these 3-D specific biological changes remains to be elucidated.
Results: Among the genes that were upregulated by oncogenic KRAS in this model, we focused on the
phosphodiesterase 4B (PDE4B) of which expression levels were found to be higher in clinical tumor samples from
CRC patients in comparison to those from healthy control in the public datasets of gene expression analysis.
PDE4B2 was specifically overexpressed among other PDE4 isoforms, and re-expression of oncogenic KRAS in HKe3
cells resulted in PDE4B overexpression. Furthermore, the inhibition of PDE4 catalytic activity using rolipram reverted
the disorganization of HCT116 cells into the normal physiologic state of the epithelial cell polarity by inducing the
apical assembly of ZO-1 (a tight junction marker) and E-cadherin (an adherens junction marker) and by increasing
the activity of caspase-3 (an apoptosis marker) in luminal cavities. Notably, rolipram reduced the AKT
phosphorylation, which is known to be associated with the disruption of luminal cavity formation and CRC
development. Similar results were also obtained using PDE4B2-shRNAs. In addition, increased expression of PDE4B
mRNA was found to be correlated with relapsed CRC in a public datasets of gene expression analysis.
Conclusions: These results collectively suggested that PDE4B is upregulated by oncogenic KRAS, and also that the
inhibition of PDE4 catalytic activity can induce both epithelial cell polarity and luminal apoptosis in CRC, thus
highlighting the utility of our 3-D culture (3 DC) model for the KRAS-induced development of CRC in 3-D
microenvironment. Indeed, using this model, we found that PDE4B is a promising candidate for a therapeutic target
as well as prognostic molecular marker in CRC. Further elucidation of the signaling network of PDE4B2 in 3 DC
would provide a better understanding of CRC in vivo.
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Both cell-cell and cell-extracellular matrix interactions
are critically involved in developmental programs and
provide three-dimensional (3-D) architectures in vivo
[1], and deregulation of these interactions is frequently
observed in cancer [2]. Human cancers are derived from
epithelial tissues characterized by specific cellular archi-
tectures including epithelial cell-cell junctions, which
allow the separation of apical and basolateral mem-
branes. This apical-basal cell polarity is crucial in normal
cell functions, and loss of cell polarity is a critical step in
tumorigenesis [3].
We recently demonstrated that HKe3 cell line, which
is a human colorectal cancer (CRC) HCT116 cell line
disrupted at oncogenic KRAS [4], in 3-D Matrigel cul-
ture (3 DC) manifests an organized structure resembling
a colonic crypt [5]. In this model, oncogenic KRAS was
found to be involved in the inhibition of luminal apop-
tosis, impairment of epithelial cell polarity and downre-
gulation of DNA repair genes including TP53 and
BRCA2 in a 3-D specific manner [5], suggesting that this
model could mimic the in vivo growth of the colonic
epithelium and would be useful for determining the crit-
ical genes involved in CRC development through onco-
genic KRAS-mediated signals in vivo.
We previously identified phosphodiesterase 4B
(PDE4B) as one of the differentially expressed between
HCT116 cells and HKe3 cells in this model [5]. PDE4
cyclic AMP (cAMP)-specific phosphodiesterase family
members are hydrolytic enzymes responsible for the
degradation of the second messenger cAMP in many cell
types, and the family consists of four genes (PDE4A,
PDE4B, PDE4C and PDE4D) encoding multiple isoforms
[6-8]. These isoforms can have unique functional roles
by their targeting to specific signaling complexes where
they underpin the compartmentalization of cAMP sig-
naling [9]. Notably, particular PDE4 isoforms are subject
to different regulatory influences, such as phosphoryl-
ation [10], ubiquitination [11] and activity changes
induced by interacting proteins [12]. For example, the
interaction of the disrupted in schizophrenia 1 (DISC1)
with PDE4B1 or PDE4B3 and mutations in DISC1
associates with schizophrenia [13].
PDE4 is ubiquitously expressed in inflammatory cells
and PDE4 inhibitors have a therapeutic potential for in-
flammatory diseases, including asthma, chronic obstruct-
ive pulmonary diseases, inflammatory bowel disease and
psoriasis [14]. A recent study suggests that overexpression
of PDE4 enzymes is critical for the MAPK activation by
oncogenic-RAS in melanoma cells [15], indicating the
novel strategy targeting PDE4 activity in melanoma cells
with oncogenic KRAS. However, the precise mechanism
of PDE4B in 3-D microenvironment of CRC with onco-
genic KRAS has not been addressed so far.In this study, we used a selective inhibitor of all PDE4
sub-families, rolipram [9,14,16] or PDE4B2-shRNAs, and
found that rolipram and PDE4B2-shRNAs revert the
disorganization of CRC into the normal physiologic state
of the epithelial cell in 3 DC.Results
Commonly upregulated genes between HCT116 cells in
3 DC and clinical CRC samples
To explore the genes regulated by oncogenic KRAS in
3 DC, we analyzed the microarray expression data for
HCT116 and HKe3 cells grown in 3 DC on day 6 [5]
using the GenePattern software package [17]. We
selected the 387 genes with a score of more than 10 as
the differentially expressed genes between HCT116 and
HKe3 cells grown in 3 DC (Figure 1A, Additional file: 1
Table S1). Then, out of the 387 genes selected, we fur-
ther selected 25 genes with a score of more than three
as the differentially expressed genes between 12 human
colorectal specimens and 10 colonic mucosa specimens
in a public datasets [18] (Figure 1B, C). Among the 25
genes, we focused on PDE4B, which was suggested to be
associated with luminal cavity formation [19].PDE4B is upregulated by oncogenic KRAS in 3 DC
In our microarray expression analyses, the relative ex-
pression level of PDE4B in 3 DC was increased in
HCT116 cells compared with that of HKe3 cells,
whereas the relative expression levels of the other PDE4
family members, including PDE4A, PDE4C and PDE4D,
were decreased in HCT116 cells in comparison to those
in HKe3 cells (Figure 2A).
To confirm these results, quantitative RT-PCR (qRT-
PCR) for PDE4 family was performed on HKe3 cells and
HCT116 cells in 3 DC. In HKe3 cells, PDE4B and
PDE4D were abundantly expressed than PDE4A or
PDE4C. The expression level of PDE4B in HCT116 cells
was significantly increased by 3.4-fold in comparison to
that in HKe3 cells (**P= 0.0008), whereas the expression
level of PDE4D in HCT116 cells was significantly
decreased by 183-fold in comparison to that in HKe3
cells (Figure 2B; *P= 0.01), indicating that the oncogenic
KRAS will regulate PDE4B and PDE4D positively and
negatively, respectively.
To elucidate which isoform of PDE4B or PDE4D is
exactly expressed, qRT-PCR was performed on HKe3 cells
and HCT116 cells in 3 DC. Among PDE4B and PDE4D
isoforms, the expression level of PDE4B2 in HCT116 cells
was only increased in comparison to that in HKe3 cells
(Figure 2C; *P< 0.01). On the other hand, the expression
levels of PDE4D1 and PDE4D2 in HCT116 cells were sig-
nificantly decreased in comparison to these in HKe3 cells
(Figure 2C; *P< 0.01), indicating that the oncogenic
Figure 1 Commonly upregulated genes between HCT116 cells in 3 DC and clinical CRC samples. (A) Differentially expressed genes
between HCT116 and HKe3 cells grown in 3 DC for 6 days. Dots represent the corresponding score for each gene (red, the genes upregulated in
HCT116 cells; blue, the genes upregulated in HKe3 cells). The green square represents the genes with a score of more than 10 (387 genes). (B)
Differential expressions of the 387 genes detected in (A) between 12 human colorectal tumor specimens and 10 colonic mucosa specimens from
the Hong dataset. Dots represent the corresponding score of each gene (red, the genes upregulated in CRC; blue, the genes upregulated in
normal colonic mucosa). The green square represents the genes with a score more than three (25 genes). (C) The expression pattern of the 25
genes detected in (B) in colorectal tumor specimens and in normal colonic mucosa specimens from the Hong dataset.
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regulate PDE4D1 and PDE4D2.
To confirm the oncogenic KRAS-mediated upregulation
of PDE4B, qRT-PCR was performed on HKe3 cells,
HCT116 cells and e3-MKRas #14 cells re-expressing
oncogenic KRAS. In two-dimensional culture (2 DC), the
expression levels of PDE4B in HCT116 cells and e3-
MKRas#14 cells were increased by 3.6- and 4.0-fold
(*P< 0.05), respectively, in comparison to that in the
HKe3 cells (Figure 2D). In 3 DC, the expression levels of
PDE4B in HCT116 cells and e3-MKRas#14 cells were
increased by 7.3- and 11.2-fold (*P< 0.05), respectively, in
comparison to that in the HKe3 cells (Figure 2D). These
results suggest that oncogenic KRAS in two dimensional
(2-D) and 3-D cultures upregulates the mRNA expression
of PDE4B. Furthermore, the expression levels of PDE4B in
HCT116 and e3-MKRas#14 cells in 3 DC were increased
by 2.0- and 2.8-fold (**P< 0.01), respectively, in compari-
son to those in 2 DC, whereas the expression level of
PDE4B in the HKe3 cells in 3 DC was not significantly dif-
ferent in comparison to that in 2 DC (Figure 2D). These
results together suggest that PDE4B, especially PDE4B2,
plays particular roles in the 3-D microenvironment.Formation of luminal cavities and tight junctions after
treatment with PDE4 inhibitor in HCT116 cells
To address the roles of PDE4B in cell polarity, ZO-1 (a
tight junction marker) and E-cadherin (an adherens
junction marker) were immunostained in HCT116 cells
grown in 3 DC treated with rolipram (PDE4 inhibitor)
or DMSO alone. The ZO-1 and E-cadherin assembly at
the apical surface of acini was more clearly observed in
HCT116 cells in 3 DC treated with rolipram in compari-
son to that in DMSO alone (Figure 3A). These results
indicated that rolipram induces the formation of the
junctional complexes essential for the maintenance of
the physiologic epithelial cell polarity [20] in HCT116
cells grown in 3 DC.
To confirm these results, the quantitative assays were
performed. The ratio of 3-D structures with luminal cav-
ities in HCT116 cells treated with rolipram was increased
by 2.46-fold in comparison to those treated with DMSO
alone (Figure 3B left panel; *P=0.00009), thus suggesting
that rolipram induces the formation of the luminal cavity.
The ratio of the 3-D structures with the concentrated sig-
nals for ZO-1 in the apical region of the HCT116
cells treated with rolipram increased by 7.67-fold in
Figure 2 PDE4B is upregulated by oncogenic KRAS in 3 DC. (A) Differential expressions of PDE4 family members between HCT116 cells and
HKe3 cells grown in 3 DC. Rows represent Affymetrix IDs, gene symbols and scores. Columns represent normalized expression levels of PDE4
family members. (B) mRNA expression levels for PDE4 family members in 3 DC. mRNA expression levels for PDE4 family members in HKe3 (black
bar) and HCT116 (white bar) cells grown in 3 DC. *, P< 0.05; **, P< 0.01; n.s., not significant. (C) mRNA expression levels for PDE4B and PDE4D
isoforms in 3 DC. mRNA expression levels for PDE4B in HKe3 (black bar) and HCT116 (white bar) cells grown in 3 DC. *, P< 0.01; n.s., not
significant. (D) mRNA expression levels for PDE4B in 2 DC or 3 DC. mRNA expression levels for PDE4B in HKe3 (black bar), HCT116 (white bar) and
e3-MKRas#14 (gray bar) cells grown in 2 DC or 3 DC. *, P< 0.05; **, P< 0.01; n.s., not significant.
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right panel; *P=0.00002), thus suggesting that rolipram
induces the formation of tight junctions. As the expression
levels of ZO-1 were not significantly different between
HCT116 cells treated with DMSO alone or rolipram
(Figure 3C; P=0.09), ZO-1 was properly translocated to
the tight junction at the apical surface of the 3-D struc-
tures by reduction of the activity of PDE4B.
Induction of luminal apoptosis by rolipram in HCT116
cells grown in 3 DC
To address the roles of PDE4B in the process of colonic
crypt organization, we compared the differences in cell
proliferation and luminal apoptosis between HKe3 and
HCT116 cells grown in 3 DC treated with rolipram orDMSO alone. The proliferation rate detected by Ki-67
staining in 3 DC on day 3 was not different between
HKe3 cells treated with DMSO alone and those treated
with rolipram (Figure 4A). Similar result was obtained in
HCT116 cells treated with DMSO alone and those trea-
ted with rolipram (Figure 4A). These results indicated
that rolipram does not affect cell proliferation in HKe3
or HCT116 cells grown in 3 DC on day 3.
To address whether rolipram influences luminal apop-
tosis in 3 DC, we evaluated the apoptotic activity in
HKe3 and HCT116 cells grown in 3 DC for 6 days with
DMSO alone or rolipram by detecting the signals for
cleaved caspase-3 in each 3-D structure using confocal
microscopy. Without the treatment of rolipram, the ratio
of the 3-D structures containing apoptotic cells in
Figure 3 Formation of luminal cavities and tight junctions by PDE4 inhibitor in HCT116 cells grown in 3 DC. (A) The signals for ZO-1 and
E-cadherin in HCT116 cells treated with DMSO alone or rolipram at day 6 in 3 DC. Nuclear DNA, blue; ZO-1, green; E-cadherin, red. Dots represent
luminal cavities. Scale bar = 50 μm. (B) The ratios of 3-D structures with luminal cavity (left panel) and apical ZO-1 signal (right panel). White bar
represents a relative intensity of the signal for 3 DC HCT116 cells treated with rolipram, normalized by the signal for 3 DC HCT116 cells treated
with DMSO alone (black bar). *, P< 0.0001. (C) Western blotting of ZO-1 for 3 DC HCT116 cells treated with DMSO alone or rolipram at Day 6
(lower panel) and the quantitative analysis of ZO-1 expression level (upper panel). White bar represents a relative intensity of the signal for 3 DC
HCT116 cells treated with rolipram normalized by the signal for 3 DC HCT116 cells treated with DMSO alone (black bar). n.s., not significant.
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to that for HKe3 cells (Figure 4B; *P= 0.00002), which
observation was concordant with the previous report [5].
The ratios of the 3-D structures containing apoptotic
cells in HKe3 cells treated with DMSO alone or rolipram
were not different (Figure 4B; *P= 0.25), suggesting that
rolipram does not further affect luminal apoptosis in the
cells already having developed luminal cavity. On the
other hand, the ratio of the 3-D structures containing
apoptotic cells in the HCT116 cells treated with roli-
pram was found to be increased by 2.21-fold in compari-
son to those treated with DMSO alone (Figure 4B;
*P= 0.0004), suggesting that a physiological apoptosis
can be restored by the inhibition of PDE4 catalytic
activity.
Induction of luminal apoptosis by PDE4B2-shRNAs in
HCT116 cells grown in 3 DC
To asses the direct role of PDE4B2 gene, we established
stable HCT116 transfectants expressing control shRNA
or PDE4B2-shRNAs through the use of lentivirus. A
qRT-PCR analysis showed that the expression level of
PDE4B2 mRNA in the HCT116 cells expressing thePDE4B2-shRNA #2 and #5 were significantly decreased
compared with those in HCT116 cells transfected with
the control shRNA (Figure 5A; *P< 0.005). To examine
whether PDE4B2-shRNAs affect cytoplasmic cAMP
level, we performed the enzyme-linked immunosorbent
assay for cAMP in these HCT116 cells transfected with
control shRNA or PDE4B2-shRNAs in 2-D or 3-D cul-
ture. The expected cAMP levels were detected in all cell
lines, however, the reduced expression of PDE4B2 did
not affect cytoplasmic cAMP levels as reported before
[21] in 2-D or 3-D culture (Figure 5B). To address
whether PDE4B2-shRNAs influence luminal apoptosis in
3 DC, we evaluated the apoptotic activity in these cells
grown in 3 DC for 6 days by detecting the signals for
cleaved caspase-3 using confocal microscopy. In
HCT116 cells with control shRNA, the ratio of the 3-D
structures containing apoptotic cells was decreased by
3.30- and 3.13-fold in comparison to that for HCT116
cells with PDE4B2-shRNA #2 and #5, respectively
(Figure 5C; *P< 0.005). This observation was similar
with the result obtained in Figure 3B, suggesting that a
physiological apoptosis can be restored by the direct in-
hibition of expression level of PDE4B2 mRNA.
Figure 4 Induction of luminal apoptosis by rolipram in HCT116 cells grown in 3 DC. (A) The signals for Ki-67 in HCT116 and HKe3 cells
treated with DMSO alone or rolipram at day 3 in 3 DC. Ki-67, green; F-actin, red; nuclear DNA (DAPI), blue. Scale bar = 50 μm (upper panels). The
ratio of Ki-67-positive cells in 3-D structures (lower panel). Black bar, 3-D structures treated with DMSO alone; white bar, 3-D structures treated
with rolipram. n.s., not significant. (B) The signals for cleaved caspase-3 in HCT116 and HKe3 cells treated with DMSO alone or rolipram at day 6
in 3 DC (upper panels). F-actin, red; DAPI, blue; cleaved caspase-3, green. Scale bar = 50 μm. The ratio of the 3-D structures containing apoptotic
cells (lower panel). Black bar, 3-D structures treated with DMSO alone; white bar, 3-D structures treated with rolipram. *, P< 0.001; n.s., not
significant.
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rolipram or PDE4B2-shRNAs in HCT116 cells
AKT is reported to play a major role in regulating acinar
structure [22], and PDE4B is suggested to be a selective
modulator for AKT phosphorylation at Ser473 [23].
Therefore, we examined the effect of rolipram on phos-
phorylation of AKT at S473, which is associated with
enhanced AKT activity, in CRC cells in 2 DC and 3 DC.
While the level of the AKT phosphorylation in HCT116
cells in 2 DC was not affected by rolipram, its phosphoryl-
ation was decreased by 2.70-fold in the HCT116 cells
grown in 3 DC in response to rolipram treatment
(Figure 6A and 6B; *P= 0.003). Additionally, we also eval-
uated the phosphorylation of AKT at Thr308, however,
any significant difference was not observed (Figure 5A).
Similarly, the level of the AKT phosphorylation at Ser473in HCT116 cells in 2 DC was not affected by PDE4B2
–shRNAs. On the other hand, the levels of AKT phos-
phorylation at Ser473 were decreased by 1.51- and 1.67-
fold in the HCT116 cells with PDE4B2-shRNA #2 and #5
grown in 3 DC, respectively (Figure 6C; *P< 0.05). These
results suggested that the oncogenic KRAS will disrupt
the acinar structure, in part, through the regulation of
AKT phosphorylation by increasing the activity of PDE4B
in the 3-D microenvironment.
Correlation between increased PDE4B expression and
disease relapse in CRC patients
Recent studies indicated that 3 DC mimics the early step
of metastasis process [24] and the differentially expressed
genes between organized and unorganized multicellular
structures grown in 3 DC share similarities with the
Figure 6 Reduction of AKT phosphorylation by rolipram in HCT116 cells grown in 3 DC. (A) Western blotting of AKT phosphorylation (p-
AKT) at Ser473 and Thr308, and pan-AKT for HCT116 cells treated with DMSO alone or rolipram at day 6 in 2-D or 3-D culture. (B) The
quantitative analyses of the level of p-AKT (Ser473) in HCT116 cells treated with DMSO alone or rolipram at day 6 in 3 DC. White bar represents
the relative intensity of the signal for HCT116 cells treated with rolipram, normalized by the signal for HCT116 cells treated with DMSO alone
(black bar). *, P< 0.01. (C) Upper panel shows western blotting of p-AKT (Ser473) and pan-AKT for HCT116 cells stably transfected with control
shRNA or PDE4B2-shRNAs at day 6 in 2-D or 3-D culture. Lower panel shows the quantitative analyses of the level of p-AKT in HCT116 cells stably
transfected with control shRNA or PDE4B2-shRNAs at day 6 in 3 DC. White bar represents the relative intensity of the signal for HCT116 cells
stably transfected with PDE4B2-shRNAs, normalized by the signal for HCT116 cells stably transfected with control shRNA (black bar). *P< 0.05.
Figure 5 Induction of luminal apoptosis by PDE4B2-shRNAs in HCT116 cells grown in 3 DC. (A) mRNA expression levels for PDE4B2 in
3 DC. *, P< 0.005. (B) The amount of cytoplasmic cAMP in HCT 116 cells grown in 2-D or 3-D culture. (C) The ratio of the 3-D structures
containing apoptotic cells. *, P< 0.005. mRNA expression levels for PDE4B2 in HCT116 cells with control shRNA (black bar) and PDE4B2-shRNAs
(white bar) grown in 3 DC.
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prognosis tumors [25-27]. To examine the correlation be-
tween PDE4B expression and the prognosis of clinical
colorectal tumors, we analyzed 18 genes out of 25 KRAS-
upregulated genes (Figure 1B, C) in a public datasets of
the microarray-based gene expression analyses of human
colorectal tumor specimens from 6 CRC patients in the
relapsed group and those from 10 patients in non-
relapsed group in a public datasets [28], revealing that ex-
pression of PDE4B mRNA was significantly upregulated
in the relapsed group compared with the non-relapsed
group (Figure 6), thus suggesting the critical involvement
of PDE4B in tumor progression and poor prognosis.
Discussion
In polarized cells, the inactivation of AKT is thought to
be important for the lumen formation with apoptosis in
3 DC [22,29,30]. The findings of AKT dephosphorylation
by PDE4 inhibitor, rolipram or PDE4B2-shRNAs in
HCT116 cells in 3 DC, but not in HCT116 cells in 2 DC
(Figure 4 and 5), suggesting the 3-D specific action of
PDE4B2 for cancer cells with oncogenic KRAS.
In clinical samples, increased expression level of
PDE4B mRNA was correlated with disease relapse in
CRC patients (Figure 7). Furthermore, among 25 KRAS-
upregulated genes (Figure 1B, C), the predictive power
of PDE4B expression for poor prognosis is stronger than
that of CXCR4 which is reported to be a prognostic fac-
tor for poor disease outcome [31,32]. PDE4B is also
reported to be predictive of the resistance to EGFR tyro-
sine kinase inhibitors in human lung tumors with KRAS
mutation [33]. These reports indicate that PDE4B is a
promising candidate for a prognostic marker in CRC.
Several studies have shown the effectiveness of PDE4
inhibitors. A recent study shows that resveratrol binds
with PDE4 and ameliorates aging-related metabolic phe-
notypes [34], indicating the positive health benefits
through the use of PDE4 inhibitors. In cancer, several
studies shows the anti-tumor effects of rolipram in com-
bination with forskolin were observed in different types of
cancer, including hematological [23,35,36], brain [37,38]
and skin cancers [15]. In CRC, Murata et al., reported that
the constitutive activation of PDE4 was detected in a
colon cancer cell line DLD-1, and rolipram suppressed
cellular motility [39]. McEwan et al., reported that the 10
μM (the same dose used in our study) of rolipram in com-
bination with an adenylate cyclase activator (forskolin)
induced apoptosis in colon cancer cell line KM12C [40].
These reports suggested that the apoptotic reaction was
induced through the increased stability of cAMP by PDE4
inhibitor or the increased activity of cAMP by forskolin
[40]. Notably, our study demonstrated that luminal apop-
tosis was effectively induced by rolipram alone (Figure 4)
or PDE4B2-shRNAs (Figure 5) without affectingcytoplasmic cAMP level (Figure 5B) in HCT116 cells in
3 DC, suggesting that the effect of PDE4 inhibitor is
enhanced by 3-D microenvironment and independent of
cAMP level. Indeed, ablation of PDE4B, but not PDE4A
or PDE4D, causes a major decrease in TNF production
and global change in cAMP could not be detected in
PDE4B−/− macrophage, together, suggesting PDE4B2 may
have specific role among PDE4B isoforms. For example,
PDE4B2 is highly expressed in immune cell and associated
with diffuse large B cell lymphoma [35]. In melanoma, the
increased PDE4B2 expression was observed compared
with that in melanocyte and PDE4B2 expression is neces-
sary to transform melanocyte with oncogenic NRAS [15],
implicating the effective strategy for cancer treatment by
targeting the PDE4B2.
Conclusions
This is a first report about the correlation between the
inhibition of PDE4 catalytic activity and luminal cavity
formation in CRC cells with oncogenic KRAS grown in
3 DC. Oncogenic KRAS upregulates the PDE4B expres-
sion and the inhibition of PDE4 catalytic activity by roli-
pram or the PDE4B2-shRNAs triggers the induction of
polarity, apoptosis and AKT dephosphorylation in
HCT116 cells grown in 3 DC, thus suggesting the
increased PDE4B2 activity will be crucial in the inhib-
ition of luminal apoptosis in colorectal epithelium in
3-D microenvironment. Further elucidation of the pre-
cise molecular mechanisms of function of PDE4B would




The anti-Ki-67 (SP6) was obtained from Thermo Scien-
tific (Rockford, IL). The anti-ZO-1 (1/ZO-1) and anti-E-
cadherin (36/E-cadherin) were from BD Biosciences
(San Jose, CA). Anti-cleaved caspase-3 (5A1), anti-
phosphorylated AKT (p-AKT; D9E) and the anti-AKT
(pan; C67E7) were from Cell Signaling Technology (Bev-
erly, MA). The anti-actin (A2066), the PDE4 inhibitor,
rolipram and 4′,6-diamidino-2-phenylindole (DAPI)
were from Sigma-Aldrich (St Louis, MO).
Cell culture
Human CRC HCT116 cells were obtained from the
American Type Culture Collection (Frederick, MD). Two-
dimensional (2-D) culture (2 DC) of HCT116 cells, HKe3
cells and e3-MKRas#14 cells (HKe3-derived stable trans-
fectants expressing oncogenic KRAS) was done as
described previously [4,5,41]. The 3 DC was performed
using Matrigel, a reconstituted basement membrane
(Growth Factor Reduced Matrigel; BD bioscience), as
described previously [5,42]. All cell lines used were
Figure 7 Correlation between increased PDE4B expression and disease relapse in CRC patients. Differential expressions of 18 genes
between colorectal tumor specimens from six CRC patients in the relapsed group and those from 10 patients in non-relapsed group in Bandrès
dataset. Dots in upper panel represent the score (red, upregulated genes in relapsed group; blue, upregulated genes in non-relapsed group).
Arrowhead represents PDE4B. Columns in lower panel represent normalized expression levels of PDE4B in 16 Dukes' B colorectal tumor
specimens.
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the MycoAlert system (Lonza, Verviers, Belgium). Cell
morphology was regularly checked to ensure the absence
of cross-contamination of cell lines.
Microarray expression analysis
Total RNA from cells in 3 DC was extracted as described
previously [5,43]. Human Genome U133 Plus 2.0 Array
6800 GeneChips (Affymetrix, Santa Clara, CA) containing
54,675 oligonucleotides were processed with the use of
robust multi-chip averaging [44]. The differentially
expressed genes between two classes were ranked accord-
ing to signal-to-noise metric with the GenePattern soft-
ware package [17,45]. The statistical significance of the
differentially expressed genes was determined by the com-
parative marker selection module in Gene-Pattern [17].
Dataset source
The Hong dataset, consisting of the microarray profiles
of human colorectal tumor specimens from 12 CRC
patients and colonic mucosa specimens from 10 healthy
control subjects [18], was obtained from the Gene Ex-
pression Omnibus (GEO; Series GSE4107). The Bandrès
dataset, consisting of human Dukes' B colorectal tumors
from 16 CRC patients with associated clinical data [28],
was also obtained from the GEO (Series GSE2630). GEO
series records were imported by the import module in
the GenePattern software package [17]. The platform
used for Hong dataset was Human Genome U133 Plus2.0 Array 6800 GeneChips (Affymetrix), which was iden-
tical to our previous study [5]. As the platform used for
Bandrès dataset was Human 19 K Oligo array slides
(Center for Applied Genomics, University of Medicine
of New Jersey), 25 probe set IDs in Human Genome
U133 Plus 2.0 Array 6800 GeneChips (Affymetrix) were
converted to gene symbols and 18 genes were identified
out of the 25 probe set IDs.
Quantitative RT-PCR
Quantitative RT-PCR was performed using ABI PRISM
7900HT (Applied Biosystems, Carlsbad, CA) as des-
cribed previously [5,43]. The PCR primer sequences
used for PDE4 isoforms and the accession numbers for
the genes are listed in Additional file: 2 Table S2. The
PCR primers used for PDE4A (pan), PDE4C (pan) and
PDE4D (pan) were designed to amplify a 3’ fragment
found in all PDE4 sub-families as reported before [7].
The PCR primers used for PDE4B (pan) were designed
to amplify a fragment characteristic of human PDE4B1
and PDE4B2 as reported before [7]. The PCR primers
used for PDE4B and PDE4D isoforms were designed as
described previously [46]. The relative expression unit
(REU) values were determined by the setting REU of
HKe3 in 2 DC as 1.0.
Immunofluorescence labeling and confocal microscopy
The immunofluorescence experiments were performed
as described previously [5,47]. For the examination of
Tsunoda et al. Molecular Cancer 2012, 11:46 Page 10 of 12
http://www.molecular-cancer.com/content/11/1/463-D structures, TCS-SP5 Laser Scanning confocal mi-
croscopy (Leica, Wetzlar, Germany) was used.
Quantification of apical ZO-1 signals and luminal cavities
in 3-D structures
The cells were stained with an anti-ZO-1, anti-E-
cadherin antibody and DAPI on day 6, and the ratio of
3-D structures with ZO-1 signals and the luminal cav-
ities in the apical region were counted as described pre-
viously [5]. A total of 60 of the 3-D structures from
three different wells were counted.
Quantification of proliferative cells grown in 3 DC
The cells were stained with the anti-Ki-67 antibody, DAPI
and phalloidin on day 3. The ratio of Ki-67-positive cells
in the total cells contacting matrigel in the cross-section
of 3-D structures at maximum diameter was calculated as
described previously [5]. The number of 3-D structures
evaluated for each condition was 20.
Quantification of apoptosis in 3-D structures
The cells were stained by anti-cleaved caspase-3 anti-
body, DAPI and phalloidin on day 6. The cleaved
caspase-3-positive cells in 3-D structures were counted
in the serial cross-sections of the 3-D structure ranged
from 60 to 130 μm in the maximum diameter. The
3-D structures containing more than two positive cells
with luminal cavity or actin assembly at the apical sur-
face of acini were defined as the 3-D structure con-
taining apoptotic cells. A total of 60 of the 3-D
structures from three different wells were counted.
The 3-D structures of HCT116 and HKe3 cells were
analyzed in three independent experiments, and the
average ratio of the 3-D structures containing apop-
totic cells was calculated as described previously [5].
Western blotting analysis
The western blotting analyses were performed as
described previously [5]. The actin intensity was used
as a control in the western blot analyses for ZO-1,
and the relative intensity of the signal (ZO-1/Actin)
was normalized to the signal-intensity in HCT116
cells treated with DMSO alone (as 100%). Pan-AKT
intensity was used as a control in the western blotting
analyses for p-AKT, and the relative intensity of the
signal (p-AKT/pan-AKT) was normalized to the signal
intensity in HCT116 cells treated with DMSO alone
as 100%.
Generation of lentivirus vectors expressing PDE4B2-
shRNAs
The short hairpin interfering RNA (shRNA) targeting
GFP was used as a control. For PDE4B2 knockdown,
shRNAs were designed based on the sequenceinformation from PDE4B2-siRNAs used in the study
for diffuse large B-cell lymphoma [35]. The shRNA
duplexes used were: PDE4B2-shRNA #2 top, 5’-CAC
CGC CTA AAC AAT ACA AGC ATT TCA AGA
GAA TGC TTG TAT TGT TTA GGC-3’ and
PDE4B2-shRNA #2 bottom, 5’-AAA AGC CTA AAC
AAT ACA AGC ATT CTC TTG AAA TGC TTG
TAT TGT TTA GGC-3’; PDE4B2-shRNA #5 top, 5’-
CAC CGC ATC TCA CGC TTT GGA GTT TCA
AGA GAA CTC CAA AGC GTG AGA TGC-3’ and
PDE4B2-shRNA #5 bottom, 5’- AAA AGC ATC TCA
CGC TTT GGA GTT CTC TTG AAA CTC CAA
AGC GTG AGA TGC-3’. The shRNA expression vec-
tors were constructed as described previously [48]. In
brief, The human U6 promoter (Gene bank accession
#M14486 gene sequence 65–329) was inserted into
ClaI and SalI sites of the pLenti6/V5-Dest (Invitrogen,
Carlsbad, CA, USA), and then U6-term was inserted
into the SalI and MluI sites to form pLenti6-U6
+ term. The resulting pLenti6-U6 + term was then
cleaved with BsmBI to form a cloning site for double-
stranded synthetic oligonucleotide DNA.
shRNA transfection
The shRNA expression vectors were transfected into
293FT cells to produce packaged lentivirus. The lenti-
virus particles were packaged using the ViraPower Lenti-
viral Expression System (Invitrogen). The HCT116 cells
were then infected with lentivirus PDE4B2-shRNAs to
obtain stably transfected clones. Blasticidin (Invitrogen)
was added to eliminate the cells not expressing PDE4B2-
shRNAs.
cAMP analysis
Cytoplasmic protein extraction was performed using
NE-PER Nuclear and Cytoplasmic Extraction Reagent
(Thermo Scientific) according to the manufacturers
instructions. cAMP levels of cytoplasmic extract from
2-D or 3D culture were measured using the direct
cAMP ELISA kit (Enzo Life Sciences, Farmingdale,
NY, USA) according to the manufacturer’s instructions.
Statistical analysis
The data are presented as the means ± standard devi-
ation. The statistical analyses were performed using un-
paired two-tailed Student’s t-test. Differences at P< 0.05
were considered to be statistically significant.
Additional files
Additional file 1: Additional Table 1. Upregulated genes by
oncogenic KRAS in 3 DC (HCT116/HKe3 in 3 DC; Score> 10.00; 387
genes).
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